Scarica l'app Stockscreener
1.20
6.98%
-0.09
Dopo l'orario di chiusura:
1.20
Precedente Chiudi:
$1.29
Aprire:
$1.28
Volume 24 ore:
463.30K
Relative Volume:
0.71
Capitalizzazione di mercato:
$107.21M
Reddito:
-
Utile/perdita netta:
$-166.14M
Rapporto P/E:
-0.6218
EPS:
-1.93
Flusso di cassa netto:
$-139.92M
1 W Prestazione:
+14.29%
1M Prestazione:
+27.77%
6M Prestazione:
+16.50%
1 anno Prestazione:
-54.55%
Intervallo 1D:
$1.20
$1.38
Intervallo di 1 settimana:
$1.01
$1.38
Portata 52W:
$0.535
$3.36
Allakos Inc Stock (ALLK) Company Profile
Nome
Allakos Inc
Settore
Industria
Telefono
650-597-5002
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Confronta ALLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
1.20 | 107.21M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-17 | Downgrade | Jefferies | Buy → Hold |
| 2024-01-16 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-18 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-08 | Ripresa | Jefferies | Buy |
| 2023-09-27 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-05-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-07 | Iniziato | Piper Sandler | Overweight |
| 2022-09-12 | Downgrade | SMBC Nikko | Neutral → Underperform |
| 2021-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-12-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-07-15 | Iniziato | Cowen | Outperform |
| 2021-05-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-15 | Iniziato | BofA Securities | Buy |
| 2020-12-21 | Iniziato | SVB Leerink | Outperform |
| 2020-02-27 | Iniziato | Barclays | Underweight |
| 2020-02-04 | Ripresa | Goldman | Neutral |
| 2018-08-13 | Iniziato | Goldman | Neutral |
| 2018-08-13 | Iniziato | Jefferies | Buy |
| 2018-08-13 | Iniziato | William Blair | Outperform |
Mostra tutto
Allakos Inc Borsa (ALLK) Ultime notizie
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - The Eastern Progress Online
BNP Paribas Financial Markets Sells 103,658 Shares of Allakos Inc. (NASDAQ:ALLK) - Defense World
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
Fmr LLC Increases Stock Holdings in Allakos Inc. (NASDAQ:ALLK) - Defense World
Fmr LLC Buys 685,623 Shares of Allakos Inc. (NASDAQ:ALLK) - MarketBeat
Allakos's SWOT analysis: AK006 potential drives stock outlook amid challenges - Investing.com Australia
1,750,000 Shares in Allakos Inc. (NASDAQ:ALLK) Bought by Point72 Asset Management L.P. - MarketBeat
Allakos Reports Q3 2024 Results and Research Progress - TipRanks
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy - MSN
Allakos Inc. finalizes early lease termination, incurring $2.5 million in costs - Investing.com Canada
Allakos Inc. Alters Lease Agreement for Cost Savings - TipRanks
FMR LLC's Strategic Acquisition of Allakos Inc Shares - GuruFocus.com
Allakos's SWOT analysis: biotech firm's stock faces hurdles in CSU market - Investing.com
FY2024 EPS Estimates for Allakos Raised by Leerink Partnrs - MarketBeat
Allakos Runs Up Into A Near-Term Catalyst (NASDAQ:ALLK) - Seeking Alpha
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
10 Health Care Stocks Whale Activity In Today's SessionAllakos (NASDAQ:ALLK), Amgen (NASDAQ:AMGN) - Benzinga
Allakos perks up after early-stage data for lead asset - MSN
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Allakos Inc. (NASDAQ:ALLK) Short Interest Down 17.1% in October - MarketBeat
3 US Penny Stocks With Market Caps Larger Than $50M - Simply Wall St
Allakos Insiders Miss 24% Gain After Offloading Stock - Simply Wall St
Vernal Keratoconjunctivitis Market Growth to Accelerate - openPR
The Manufacturers Life Insurance Company Sells 2,148 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Short Interest in Custom Truck One Source, Inc. (NYSE:CTOS) Decreases By 5.5% - Defense World
Nasal Polyposis Market Size is Set for Rapid Growth as Innovative - openPR
Chronic Spontaneous Urticaria Market Forecasted to Surge - openPR
Jefferies downgrades Allakos Inc (ALLK) stock to a Hold - Knox Daily
Allakos Inc (ALLK)’s stock price range in the last year - US Post News
Investor’s Delight: Allakos Inc (ALLK) Closes Weak at 0.65, Down -1.14 - The Dwinnex
Allakos shares hold rating after trial update By Investing.com - Investing.com Australia
Piper Sandler maintains Overweight rating on Allakos shares By Investing.com - Investing.com Australia
TD Cowen Reiterates Hold Rating on Allakos Inc. (ALLK) - StreetInsider.com
Piper Sandler maintains Overweight rating on Allakos shares - Investing.com India
Allakos shares hold rating after trial update - Investing.com
Allakos stock gains on trial data for lead drug (NASDAQ:ALLK) - Seeking Alpha
Piper Sandler Reiterates Overweight Rating on Allakos Inc. (ALLK) - StreetInsider.com
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - ForexTV.com
Allakos reports positive results from AK006 Phase 1 study - Investing.com India
Allakos Progress Update on AK006 and Future Milestones - TipRanks
Allakos reports positive results from AK006 Phase 1 study By Investing.com - Investing.com UK
Allakos (ALLK) Reports Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - StreetInsider.com
SG Americas Securities LLC Grows Stake in Stellantis (NYSE:STLA) - Defense World
Allakos Inc Azioni (ALLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):